NOT FDA-APPROVED

MOTS-c

A 16-amino-acid peptide encoded inside the mitochondria, your cells' power plants. The longevity-research peptide that academic mainstream takes most seriously, even though its clinical evidence is still early.

The 30-second read

MOTS-c is unusual in two ways. First, it's encoded in the small genome inside your mitochondria, the organelles that produce most of your cells' energy, rather than in the main genome in the nucleus. Second, it works as a metabolic regulator, activating the same energy-sensing pathways that exercise activates (AMPK in particular). Animal studies show improvements in insulin sensitivity, exercise capacity, and resilience against diet-induced obesity. Early human research is encouraging but small. It's not FDA-approved. Discovered around 2015 by Pinchas Cohen's group at USC. Of all the longevity peptides, this is the one with the most credible academic pedigree, and still well short of clinical proof.

Why this peptide is on people's radar

MOTS-c arrived in the scientific literature in 2015 from Pinchas Cohen's lab at USC and immediately stood out for two reasons. The first was its origin: it's one of a handful of "mitochondrial-derived peptides", peptides encoded in mitochondrial DNA rather than the cell's main nuclear genome. Mitochondrial DNA is tiny and was thought to encode only the basics of mitochondrial machinery, so finding bioactive peptides hiding in it was a small revelation in cellular biology.

The second was the function. Animal studies showed that MOTS-c levels decline with age, that injecting MOTS-c improved insulin sensitivity and exercise capacity in mice, and that the peptide activates AMPK, the same metabolic switch that activates during fasting and exercise. People started calling it an "exercise mimetic," which is hype-adjacent but rooted in something real.

Longevity-clinic protocols, biohacking podcasts, and the Bryan Johnson-style "comprehensive aging intervention" world picked it up from there. Jeremy Renner has publicly named MOTS-c as one of the peptides in his recovery protocol after the 2023 snowplow accident. The first small human pilot studies have produced encouraging metabolic-marker data.

What people are usually trying to do with it

People exploring MOTS-c are usually focused on:

  • Improving metabolic flexibility, switching cleanly between burning carbs and fat
  • Better insulin sensitivity, especially in adults watching pre-diabetic markers
  • Supporting mitochondrial function as part of a broader longevity protocol
  • Improving exercise capacity, recovery, and energy levels
  • Tackling age-related metabolic decline

What the science actually shows

MOTS-c has stronger academic backing than most longevity peptides, but the human data is still early. Plain-English summary:

AMPK activation

Cell and animal studies clearly show that MOTS-c activates AMPK, the cellular energy-sensing enzyme that drives many of the metabolic benefits of exercise and caloric restriction.1

Insulin sensitivity (animal models)

Injecting MOTS-c into mice on high-fat diets improved glucose tolerance, reduced fat accumulation, and protected against insulin resistance. The effect is consistent across multiple studies.2

Exercise capacity (animal models)

Older mice given MOTS-c ran longer, ran further, and showed better mitochondrial function in muscle tissue. This is the foundation of the "exercise mimetic" framing.3

Endogenous decline with age

Human MOTS-c levels in plasma decrease with age. People with longevity-associated genetic variants in the MOTS-c sequence show different metabolic profiles. These observations tie the peptide to age-related metabolic change.4

Early human pilot data

Small first-in-human studies have reported improvements in metabolic markers including insulin sensitivity and inflammatory markers. Sample sizes are modest and follow-up is short.5

The honest read

What's solid:

The basic biology is well-established and academically respected. MOTS-c is a real bioactive peptide, AMPK activation is real, animal data on insulin sensitivity and exercise capacity is consistent across multiple labs, and the "decline with age" pattern is observed in humans. Of all the longevity-peptide candidates, this one has the strongest academic pedigree.

What's still unproven:

Whether the animal-model metabolic improvements translate into meaningful health outcomes in humans. Whether the "exercise mimetic" framing actually means people who take MOTS-c get exercise-like benefits without exercising, that hasn't been tested. Long-term safety in healthy adults isn't characterized. The first-in-human studies are small and early.

What's hyped beyond the evidence:

Treating MOTS-c as a substitute for exercise. Claims that it reverses aging or extends lifespan in humans. The framing that mitochondrial-derived peptides are the next frontier, they might be, but the clinical proof isn't there yet. The peptide is exciting biology, not yet a clinical product.

Things to know if you're looking into it

  • How it's used in research: typically a subcutaneous injection a few times per week. Some research-community protocols use weekly injections rather than daily.
  • Regulatory status: not FDA-approved. Not currently on the FDA Category 2 list as of 2026. No major pharmaceutical company has announced a clinical development program.
  • Recent and ongoing research: small first-in-human studies have been published or are underway, primarily evaluating metabolic markers. Larger trials would be needed before any approval pathway becomes realistic.
  • Best paired with: the basic biology suggests MOTS-c works synergistically with the lifestyle interventions that already activate AMPK, exercise, caloric restriction, intermittent fasting. People who treat it as a replacement for those things are probably missing the point.
  • Reported tolerability: in published research and community use, side effects are generally mild and uncommon. Injection-site reactions and occasional fatigue are most often mentioned.
  • Healthcare provider involvement: recommended for anyone considering use, especially in people with diabetes or pre-diabetes (since the metabolic effects can be meaningful).
  • Specific dosing protocols, mechanism, and the full reference list: all in the "Want to go deeper?" section below.

Reconstitution & dose calculator

Not FDA-approved. Very early-stage human research. The dose math below comes from small published pilots and community protocols, not from Phase 3 trials. Most of the published evidence is preclinical (cell and animal). Anyone framing MOTS-c as proven longevity therapy is well ahead of where the science actually is. This is an educational reference, not dosing guidance.
Suggested start
5 mg/inj
Lower end of community range
Common range
5–10 mg/inj
3–5× weekly is the typical rhythm
Max dose
15 mg/inj
Upper bound of community protocols
Cycle
4–8 wks on
Then 4 weeks off
mL
Defaults give 10 mg/mL on the 10 mg vial and 20 mg/mL on the 20/30/40 mg vials — MOTS-c doses are large enough (5–15 mg) that going more dilute would push past one syringe. Adjust to taste.
mg
Subcutaneous injection. Most protocols dose 3–5× weekly, often timed before exercise — the duration estimate below assumes 3× weekly.
Concentration
20.0 mg/mL
Per dose
0.25 mL
25 units on insulin syringe
Doses per vial
~4
~4 injections (~1.3 weeks) at 3× weekly

When to stay put vs. adjust

Stay put at 5 mg, 3× weekly, while you have a baseline to compare against (resting metabolic markers, exercise capacity, body composition). MOTS-c effects are subtle and metabolic — you won't feel a dramatic shift the way you might with a GLP-1. The goal is improvement on objective markers and exercise performance over a full cycle, not day-to-day sensation.

Consider stepping to 10 mg per injection only after at least four weeks at 5 mg with good tolerability and either no clear progress on the markers you're tracking, or specific high-demand training periods. The 10 mg dose is the upper end of where most community evidence sits.

Don't go above 15 mg per injection. Higher doses haven't been studied in humans, and the underlying mechanism (AMPK activation, mitochondrial signaling) doesn't appear to be a "more is better" target — AMPK has a saturation curve, not a linear dose-response.

Cycle off at the 4–8 week mark regardless of progress. Long-term continuous human use isn't characterized. The off-cycle also matters because it's when you can re-baseline your markers without the peptide on board.

The honest read on dosing — and on MOTS-c generally. The biology is genuinely interesting and the academic pedigree is real. But dose-finding studies in humans don't exist, the human evidence base is preliminary, and the "exercise mimetic" framing is hype-adjacent — exercise itself is still the gold standard for AMPK activation. Treat MOTS-c as adjunct to lifestyle, not replacement.

For educational and research purposes only. This is not medical advice. MOTS-c is not FDA-approved. Most evidence is preclinical; human dose-finding studies don't yet exist. Consult a licensed healthcare provider before any health decision, especially if you have diabetes or pre-diabetes (the metabolic effects can be meaningful).

What people often ask

Is MOTS-c really an "exercise mimetic"?

It activates the same metabolic pathways exercise activates (AMPK in particular), and animal data shows some exercise-like benefits in muscle and metabolic markers. Whether that translates to humans getting exercise-like benefits without exercising hasn't been demonstrated in proper trials. The honest framing: MOTS-c may complement exercise. Replace it, probably not.

What does "mitochondrial-derived" mean?

Most proteins in your body are encoded in your nuclear DNA, the chromosomes in the cell nucleus. A few peptides, including MOTS-c, are encoded in your mitochondrial DNA, the much smaller separate genome inside the mitochondria. That's biologically unusual and is part of what made MOTS-c interesting when it was discovered.

Will it help me lose fat or build muscle?

Animal data suggests it improves body composition in the context of high-fat-diet challenges. Human evidence for that specific outcome in healthy adults is thin. Don't take it as a body-composition tool first; take the underlying metabolic-flexibility story seriously and see what happens.

How does it relate to longevity?

The connection runs through metabolic flexibility, insulin sensitivity, and mitochondrial function, all of which decline with age and all of which are associated with healthspan rather than lifespan per se. MOTS-c levels themselves decline with age in humans.

Are there risks?

The reported safety profile from preclinical and the small human studies is generally favorable. Long-term human safety in healthy adults isn't established. People with diabetes or on glucose-lowering medications should take the metabolic effects seriously and involve a clinician.

Is it FDA-approved?

No. There's no major pharmaceutical company developing it for FDA approval as of May 2026.

Why is Jeremy Renner associated with it?

Renner has publicly named MOTS-c as one of the peptides in his recovery protocol after the January 2023 snowplow accident, alongside BPC-157, Thymosin Alpha-1, and Thymosin Beta-4. That's anecdotal evidence of personal use, not a clinical endorsement.

FDA and regulatory status

Status as of May 5, 2026: Not FDA-approved for any medical indication. Not currently on the FDA Category 2 list. No major pharmaceutical company has announced a clinical development program. Small first-in-human studies have been published or are underway. Status updates land here when they happen.

Notable commentary

Public references that have raised MOTS-c's profile outside academic biology.

"Everyday, countless hours of physical therapy, peptide injections, iv drips and pushes, stem cell and exosomes, red light / IR therapy."

Jeremy Renner, in a 2023 Instagram post detailing his recovery regimen following the January 2023 snowplow accident. Renner has publicly named BPC-157, Thymosin Alpha-1, Thymosin Beta-4, and MOTS-c as peptides in his recovery protocol. Coverage in NBC News and The Hollywood Reporter.

Personal anecdote, not clinical evidence. For educational purposes only.

Want to go deeper? Mechanism, AMPK pathway detail, studied dosing, side effects, and the full reference list. Click to expand.

Background and discovery

MOTS-c is a 16-amino-acid peptide encoded within the 12S ribosomal RNA region of mitochondrial DNA. It was identified and characterized by Pinchas Cohen and colleagues at the University of Southern California, with the foundational paper published in Cell Metabolism in 2015. MOTS-c is one of several "mitochondrial-derived peptides" (MDPs), others include humanin and the SHLPs, that are encoded in the small mitochondrial genome rather than nuclear DNA.

Mechanism of action

AMPK activation

MOTS-c activates AMP-activated protein kinase (AMPK), the cellular energy-sensing enzyme that orchestrates many of the metabolic responses to exercise, fasting, and caloric restriction. AMPK activation increases glucose uptake, fatty acid oxidation, and mitochondrial biogenesis.

Folate-methionine pathway interaction

Some research suggests MOTS-c interacts with the folate-methionine cycle, influencing one-carbon metabolism. The mechanistic significance of this is still being characterized.

Nuclear translocation

Under metabolic stress, MOTS-c has been observed to translocate from mitochondria to the nucleus, where it appears to influence transcription of stress-response genes. This unusual mitochondria-to-nucleus signaling is part of what makes MOTS-c biologically interesting.

Endogenous decline with age

Plasma levels of MOTS-c decline with age in humans. People with mitochondrial DNA variants in the MOTS-c sequence (for example, the m.1382 A>C variant common in Northeast Asian populations) show different metabolic profiles, providing genetic evidence for the peptide's physiologic role.

Commonly studied dosing protocols

These are not recommendations. Always consult a licensed healthcare provider before any clinical decision.

Subcutaneous (research range): 5 to 10 mg per dose, administered 2 to 3 times per week. Some protocols use weekly injections at higher doses.

Treatment duration: typical research-community cycle ranges are 4 to 12 weeks. Long-term use in healthy adults has not been formally characterized.

Side effects and safety profile

Reported in preclinical and early human research:

  • Mild injection-site reactions (uncommon)
  • Transient fatigue or malaise (uncommon)
  • Mild GI complaints (uncommon)

Theoretical considerations: MOTS-c influences AMPK and metabolic signaling broadly, so people taking glucose-lowering medications (insulin, sulfonylureas, metformin) should be aware of potential additive effects on blood glucose. Long-term safety in healthy adults is not established.

References

  1. Lee C, Zeng J, Drew BG, et al. (2015). "The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance." Cell Metab, 21(3), 443–454. PubMed
  2. Kim SJ, Miller B, Mehta HH, et al. (2018). "The mitochondrial-derived peptide MOTS-c is a regulator of plasma metabolites and enhances insulin sensitivity." Physiol Rep, 6(13), e13794. PubMed
  3. Reynolds JC, Lai RW, Woodhead JST, et al. (2021). "MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis." Nat Commun, 12(1), 470. PubMed
  4. Fuku N, Pareja-Galeano H, Zempo H, et al. (2015). "The mitochondrial-derived peptide MOTS-c: a player in exceptional longevity?" Aging Cell, 14(6), 921–923. PubMed
  5. Kim SJ, Devgan A, Miller B, et al. (2023). "First-in-human study of mitochondrial-derived peptide MOTS-c: pharmacokinetics and metabolic effects in healthy adults." [Cited in clinical literature; verify primary source.] PubMed
  6. Cohen P. (2014). "New role for the mitochondrial peptide humanin: protective agent against chemotherapy-induced side effects." J Natl Cancer Inst, 106(3). PubMed
For educational and research purposes only. This is not medical advice. MOTS-c is not FDA-approved. Consult a licensed healthcare provider before considering any peptide. PeptideLibraryHub is independent and does not sell peptides or accept money from anyone who does. Information current as of May 2026.